About us

Creative thinking inspires
ideas and those ideas
inspire change.

Learn more

Vision

Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success. 

Our mission is to create the leading global innovation network to generate transformational healthcare solutions through value-creating partnerships.

Listen to Paul Stoffels, M.D., Executive Vice President and Chief Scientific Officer, Johnson & Johnson discuss the value of collaboration.

Family

Johnson & Johnson Innovation is comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration. Our family brings expertise across all sectors: consumer, medical devices, pharmaceuticals and global public health.

Johnson & Johnson Innovation | JLABS and Johnson & Johnson Innovation | JLINX

Johnson & Johnson Innovation has developed a global network of incubators and incubation partnerships to support entrepreneurs launching consumer, medical device, or biopharmaceutical companies. If you are seeking incubation space for your early-stage company, or seeking to expand your start-up through an exchange of ideas and collaboration, make the connection with our incubation teams.

Johnson & Johnson Innovation | Innovation Centers

Innovation Centers—located in Boston, California, London and Shanghai—are Johnson & Johnson Innovation regional hubs, created to access the best science and technology in the region. If you are an entrepreneur or with an early-stage consumer or medical device company, or a biopharmaceutical company seeking a collaboration to advance a program which is pre-proof of concept in humans, make the connection with our Johnson & Johnson Innovation team.

Johnson & Johnson Innovation | JJDC, Inc.

Johnson & Johnson Innovation – JJDC, Inc., the strategic venture arm of Johnson & Johnson, invests across all sectors and at all stages, from seed-level start-ups to Series B and beyond. If you are seeking a strategic venture partner, make the connection with our JJDC team.

Johnson & Johnson Innovation | Janssen Business Development

Johnson & Johnson Innovation, Janssen Business Development seeks to identify collaborative opportunities that will create transformative value for our partners and the world. If you are an established pharmaceutical company, or mid-sized to large biotechnology company, and seek a collaboration or merger & acquisition discussion, make the connection with our Johnson & Johnson Innovation, Janssen Business Development team.

Leadership

We are led by a unique team of business and science experts who have experience in bringing early-stage innovations to commercialization.

  • Paul Stoffels
    Executive Vice President, Chief Scientific Officer
  • Robert Urban
    Global Head, Johnson & Johnson Innovation
  • James J. Bergin
    Vice President, Law
  • Rowan Chapman
    Head, Johnson & Johnson Innovation, California
  • Tom Heyman
    President JJDC
  • Seema Kumar
    Vice President of Innovation, Global Health and Policy Communication
  • Meghan Marschall
    Global Innovation Communication Leader
  • Richard Mason
    Head, Johnson & Johnson Innovation, London
  • Melinda Richter
    Head of JLABS, Johnson & Johnson Innovation
  • Patricia Monteiro de Araujo
    Human Resources Director, External Innovation
  • Darren Snellgrove
    Vice President of Finance and Chief Financial Officer
  • Dong Wu
    Head, Johnson & Johnson Innovation, Asia Pacific
  • Patrick Verheyen
    Global Head, Janssen Business Development
  • Close

    Paul Stoffels,
    MD

    Executive Vice President, Chief Scientific Officer

    Dr. Paul Stoffels is Chief Scientific Officer, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda, and is a member of the Johnson & Johnson Executive Committee.

    Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson & Johnson Development Corporation (JJDC) and Johnson & Johnson Innovation Centers, with the goal of catalyzing innovative science and technology. Additionally, he oversees product safety of all products of the Johnson & Johnson Family of Companies worldwide.

    Paul is also Worldwide Chairman, Pharmaceuticals, Johnson & Johnson, with responsibility for expansion of the company’s therapeutic pipeline through global R&D and strategic partnerships, licensing and acquisitions. He oversees teams across the Janssen Pharmaceutical Companies of Johnson & Johnson, which discover and develop treatments for unmet medical needs in the therapeutic areas of cardiovascular & metabolism, immunology, infectious disease & vaccines, neuroscience and oncology.

    Prior to his role as Worldwide Chairman, Paul served as Global Head, Johnson & Johnson Pharmaceutical R&D from 2009 - 2011, as Company Group Chairman, Central Nervous System & Internal Medicine, from 2006 - 2009, and as Company Group Chairman, Global Virology, from 2005-2006. Paul joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of a number of leading products for the treatment of HIV.

  • Close

    Robert Urban,
    PhD

    Global Head, Johnson & Johnson Innovation

    Robert is Head of the Johnson & Johnson Innovation, Boston. He joined the Johnson & Johnson Family of Companies from the Massachusetts Institute of Technology, where he was the founding Executive Director of the Koch Institute for Integrative Cancer Research. In this role, Robert worked to build the Koch Institute into a new standard for interdisciplinary disease-focused research via an expanding, highly-effective, relationship network with other academic oncology centers, industrial partners, cancer-focused philanthropists and investors. During Robert’s tenure, the Koch Institute launched 17 start-up companies and its technology was the source of more than 50 out-licensing transactions.

    Robert was recruited to MIT from Acretia Inc. – a product acquisition and out-licensing company where he was the President and CEO. During his time at Acretia Inc. the organization conducted technical due diligence on more than 280 product opportunities and completed the acquisition of three distinct product lines.

    Prior to this, Robert held a variety of business development and clinical development roles in the pharmaceutical industry. He has worked in the areas of oncology, HPV, anti-inflammatory and infectious diseases. His experience includes clinical product development, operations oversight, licensing and acquisitions, capital fund raising, company creation, and building relationships with key thought-leaders.

    Robert received his Bachelor of Arts degree in Microbiology and his PhD in Microbiology and Immunology from the University of Texas system, and was an Irvington Fellow in structural immunology at Harvard University.

  • Close

    James J. Bergin

    Vice President, Law

    James has provided legal counsel to the leadership team of Johnson & Johnson Innovation since February 2015 and leads the global Johnson & Johnson legal team dedicated to Johnson & Johnson Innovation.

    James is a passionate advocate for innovation and its important role in addressing unmet medical need and contributing to business success. He has been at the forefront of a number of innovative initiatives throughout his career at Johnson & Johnson.

    Prior to his current role, James was Regional Counsel for Janssen Asia Pacific and a member of its regional leadership team. In this capacity, he was one of the driving forces behind the Janssen Asia Pacific Innovation Fund, supporting out-of-the-box thinking and projects that deliver for patients and Janssen. He was also actively involved in a multi award-winning employee engagement campaign around Business Integrity.

    As legal advisor to the leadership team of One Johnson & Johnson Southeast Asia until March 2015, James played a critical role in the successful launch and operation of the innovative One Company business model that united the resources and capabilities of all Johnson & Johnson businesses in this important, growing region.

    James joined Johnson & Johnson Corporate in 1997 as a general attorney in the business transaction group of the Law Department. He has served as the lead Johnson & Johnson lawyer on many acquisitions, divestitures, joint ventures and complex transactions; has been a member of seven leadership teams across a variety of Johnson & Johnson businesses; and been the legal representative for Johnson & Johnson on numerous industry initiatives. Prior to joining Johnson & Johnson, James practiced law in New York and Sydney.

  • Close

    Rowan Chapman,
    PhD

    Head, Johnson & Johnson Innovation, California

    Rowan is the Head of Johnson & Johnson Innovation, California. Rowan will lead the California team to build upon recent successes and manage a portfolio of co-investments spanning across all three sectors of Johnson & Johnson. 

    Rowan will expand her strong external networks within the innovation ecosystem and continue our efforts to identify the most promising transformational science and technology in the Pharmaceutical, Medical Device and Consumer sectors and seek to bring them into Johnson & Johnson Family of Companies. 

    Rowan and team will develop and strengthen models to leverage collaboration through flexible deal structures and investments. She will oversee sourcing, transactional and partnerships co-management activities and will leverage her unique expertise as a part of the Johnson & Johnson Innovation Leadership Team. 

    She brings with her a strong expertise and passion for building new companies, end to end digital solutions and data analytics. Rowan most recently served as Head of Healthcare Investing, GE Ventures. There she led the team responsible for GE Ventures’ healthcare investing strategy and portfolio as well as managing partnerships and thought leadership with a particular focus on digital health, data analytics and precision medicine. In this role she drove creation of the first three Healthcare “NewCos” incubated and launched from GE. 

    Prior to joining the ventures team, Rowan served as Head of Precision Diagnostics at GE Healthcare, where she was responsible for strategy development to integrate lab services, products, data, informatics, software, and content. Before GE, she spent 11 years as a Partner at Mohr Davidow Ventures, where she drove development of the life science investment strategy and practice area. Her investments ranged from therapeutics to diagnostic to digital. 

    Prior to venture capital, Rowan was a very early employee at Rosetta Inpharmatics, a healthcare data analytics company, where she executed multiple business development and partnering deals ranging from strategic to revenue generating for the company. Rowan was previously a Product Marketing Manager at Incyte Genomics where she was responsible for spearheading statistical analytics for the expression product lines as well as development of business and marketing plans for the first bacterial microarray. 

    Rowan holds a Ph.D. and first class honors degree in Biochemistry from Cambridge University, U.K. and was a post-doctoral fellow at the University of California, San Francisco. She has been involved on community projects and has a passion to make an impact on diversity. 

    Rowan lives near SFO airport with 5 chickens, 3 children and her husband.

  • Close

    Tom Heyman

    President JJDC

    Tom Heyman is President, Johnson & Johnson Development Corporation (JJDC), part of Johnson & Johnson Innovation. As head of JJDC, Tom will chair the board of JJDC, which represents the oldest and most reputable corporate venture fund in the life science industry.

    Tom will continue his position as CEO of Janssen Pharmaceutica NV in Belgium, and he continues to be responsible for campus leadership in Beerse, Belgium, as well as the development and execution of a long-term organizational and talent strategy. Tom was appointed Chairman of the Board of Directors, Janssen Pharmaceutica in March 2012. He is a member of the Board of Directors VOKA, the Flemish Industry Association, Belgium, and a member of the Board of Directors of Innotek. As of April 2012, he is a member of the Board of Directors and the General Assembly of IMEC.

    Tom started his career with Johnson & Johnson in the Legal Department of Janssen Pharmaceutica NV in 1982, where he supported legal and licensing activities. In 1990, he became Vice-President of Corporate Development at Ortho Pharmaceutical Corporation, and was later appointed Head of Global Business Development for the Pharmaceutical Group. In his 25 years in Business Development, Tom and his Group entered into hundreds of transactions for both early and late stage Pharmaceutical products and technologies including IMBRUVUCA®, daratanumab, INVOKANA®, etc. He was also responsible for acquiring several key companies for J&J including Aragon Pharmaceuticals, Covagen and Alios Biopharma. Tom has been a member of the Pharmaceuticals Group Operating Committee (GOC), and he also served as Head of the CNS/IM Research & Early Development (RED) organization.

  • Close

    Seema Kumar

    Vice President of Innovation, Global Health and Policy Communication

    Seema is a member of the Communications Leadership Council at Johnson & Johnson and responsible for maintaining the company’s leadership position in innovation and global health. She works closely with Johnson & Johnson Chief Scientific Officer and Worldwide Chairman of Pharmaceuticals, Dr. Paul Stoffels, as well as communication leaders in Corporate and R&D. Seema also serves as the communication leader for the Worldwide R&D Council and several Innovation Centers.

    Seema was previously Vice President, Global R&D Communications at The Janssen Pharmaceutical Companies of Johnson & Johnson, where she has had oversight of internal and external communications across the pharmaceutical R&D enterprise.

    Prior to joining Janssen, Seema was the chief communications officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research. She played a key role in enhancing worldwide public awareness and understanding of the Human Genome Project.

    Seema has published more than 200 news and feature articles on science and medicine, for which she has won several awards, including an Award of Excellence in writing from the American Medical Writers Association and three Gold Medals for Media Relations, Science Education, and Web Development.

    Seema holds a master’s degree in science journalism from the University of Maryland, a fellowship at the National Cancer Institute, a bachelor of science and communication from the University of Maryland, a graduate diploma in journalism and mass communication, and a bachelor of science in physics from Stella Maris College, in Madras, India.

  • Close

    Meghan Marschall

    Global Innovation Communication Leader

    Meghan is the Global Innovation Communications Leader for Johnson & Johnson Innovation. Meghan is responsible for communication initiatives across Johnson & Johnson Global Innovation Centers (JJIC), JLABS, JLINX, JJDC, and Janssen Business Development. Meghan and her team are accountable for external public affairs, media relations, global and regional activation implementing a diverse Innovation agenda across the globe.

    Previously, Meghan was the communications and External Affairs at Johnson & Johnson Innovation, California and JLABs. Meghan joined the Johnson & Johnson Family of Companies through the Pfizer Consumer Healthcare (PCH) acquisition in 2006 and began her career with several years of agency experience at Ruder-Finn and G.S. Schwartz & Co., working on a variety of business-to-business, retail and consumer clients.

    Meghan earned her Bachelor of Arts from Lafayette College.

  • Close

    Richard Mason

    Head, Johnson & Johnson Innovation, London

    Richard is the head of Johnson & Johnson Innovation, London. He joins Johnson & Johnson Innovation from XO1 Limited, where he served as CEO until the company was acquired by Janssen in March 2015.

    Prior to his role at XO1, Richard was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions.

    Richard also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT).

    Richard trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals.

    Richard resides near Cambridge, UK. In his spare time Richard enjoys skiing, running, flying and sailing.

  • Close

    Melinda Richter

    Head of JLABS, Johnson & Johnson Innovation

    As Head of JLABS, Melinda fosters Johnson & Johnson’s external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a biotech company.

    Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set-out to create a better model, which now forms the basis for JLABS’ operational infrastructure.

    Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also started, raised capital and did large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an MBA from INSEAD in France.

  • Close

    Patricia Monteiro de Araujo

    Human Resources Director, External Innovation

    Patricia is the Human Resources Director for External Innovation. Patricia provides strategic HR support globally to Johnson & Johnson Innovation, including our regional Innovation Centers, JLABS and JJDC, partnering directly with their respective Leadership teams.

    Most recently, Patricia served as the HR Director, Latin America for Global Orthopedics. During her three years supporting our Orthopedics business, among other key accomplishments, Patricia successfully partnered with all stakeholders to redesign the organization and to deliver on a talent strategy to enable business growth for the Global Orthopedics Latin America Organization. Patricia also successfully led the HR integration within six countries. Patricia began her career with Johnson & Johnson in 2009 as the HR Senior Manager in MD&D Brazil where she partnered with several franchises and worked as the Engagement Survey Champion for the region.

    Prior to her career at Johnson & Johnson, she worked for ten years at Unilever Europe and Latin America in several positions of increasing responsibility supporting different areas and businesses. Her career began at Sadia, a Brazilian Foods company based in Brazil where she worked for almost three years. Some of her key experiences have been in areas of talent, mergers and acquisitions, learning and development and change management.

    Patricia holds a bachelor degree in Psychology from PUC Campinas – Brazil, as well as a Master’s degree in Organization Consulting and Change from Ashridge Business School of the United Kingdom.

  • Close

    Darren Snellgrove

    Vice President of Finance and Chief Financial Officer

    Darren is Vice President of Finance and Chief Financial Officer for Johnson & Johnson Innovation and Johnson & Johnson Innovation – JJDC, Inc. (JJDC). Darren also provides financial support and leadership to Janssen Healthcare Innovation and Janssen Labs in La Jolla.

    Prior to joining Johnson & Johnson Innovation, Darren was the Chief Financial Officer at Janssen AI. Darren joined the Johnson & Johnson Family of Companies through the acquisition of Centocor in 1999, where he spent six years in positions of increasing responsibility and in support of a variety of functions including Commercial, R&D, and Business Development. In 2002, Darren moved to Johnson & Johnson Corporate, where he spent three years in the Mergers and Acquisitions Finance group providing financial leadership on more than 100 potential acquisitions, major licensing deals, equity investments, options, structures, and divestitures across all sectors. Darren also held senior leadership roles in companies at Scios, ALZA, and Cordis.

    Darren holds a BA Honors Degree in Economics and Philosophy from Southampton University in England, and an MBA from Villanova University.

  • Close

    Dong Wu

    Head, Johnson & Johnson Innovation, Asia Pacific

    Dong is Head of Johnson & Johnson Innovation, Asia Pacific. He joined the Innovation team from Johnson & Johnson’s Consumer business where he was Vice President of R&D, responsible for the Global Engineering Organization and leading the transformation of the emerging markets R&D groups. In that role, he led the exploration of new product opportunities for Johnson & Johnson in global markets.

    Dong joined Johnson & Johnson in 2007 as Senior Director, Head of Emerging Markets R&D where he focused on developing personal care products for emerging markets. During this time, he facilitated programs aimed at developing high value products and driving a culture of innovation.

    Prior to joining Johnson & Johnson, Dong worked at Unilever where he held various positions in Quality Assurance, Manufacturing and Research & Development. Dong became part of the team that founded the Unilever Regional Innovation Center in Shanghai, where he was acting head of the Development Laboratory. He then became Manufacturing General Manager and Site General Manager of the Hefei plant, Unilever’s largest manufacturing site worldwide. During his career at Unilever, he worked in China, the UK, the U.S. and Japan.

    Dong has a Bachelor’s degree in Applied Chemistry from Fudan University and an MBA from China Europe International Business School.

  • Close

    Patrick Verheyen

    Global Head, Janssen Business Development

    Patrick is Global Head, Janssen Business Development. In this role, Patrick leads the business development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals for the Janssen Pharmaceutical Companies of Johnson & Johnson. Patrick assumed this role in April 2015.

    Prior to this, Patrick helped design and launch Johnson & Johnson Innovation and was Head of Johnson & Johnson Innovation, London. This Innovation strategy has delivered a robust early-stage portfolio and has helped earn Johnson & Johnson a reputation as a preferred partner with external innovators, entrepreneurs, and academic institutions.

    Patrick joined Johnson & Johnson in 1986 at Janssen Pharmaceuticals in Beerse, Belgium. Previously, he was Vice President, New Ventures, Pharmaceuticals, where he led an agile and diverse team who facilitated divestitures, established strategic collaborations, and identified investments that provided Janssen with access to external innovation and early product flow. Patrick also served as Vice President, M&A, where he facilitated strategic collaborations and acquisitions including Crucell, Elan, and Cougar Biotechnology, and established spin-out companies, including Movetis. Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large capital space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations, private equity groups, and government institutions.

    Patrick studied bioengineering at the University of Leuven, Flanders, Belgium. 

Accelerators

Close
Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
mail@www.neomed.ca
www.neomed.ca
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.